BBNX Insider Files Form 144 to Sell 6,818 Shares via Merrill Lynch

Rhea-AI Filing Summary

Form 144 notice from an insider of Beta Bionics, Inc. (BBNX) indicates a proposed brokered sale of 6,818 common shares through Merrill Lynch on 09/04/2025 to be executed on the NASDAQ. The filing shows the shares were acquired in two transactions: 2,069 shares from an equity award on 09/01/2025 and 4,749 shares from a stock option exercise on 09/04/2025, with payment listed as cash. The issuer's total shares outstanding are stated as 43,470,125, and the aggregate market value of the proposed sale is $136,179.70. The filing also discloses prior sales by the same person during the past three months totaling 16,158 and 868 shares on 08/19/2025 and 06/02/2025, respectively.

Insights

Securities Analyst

TL;DR Insider proposes a modest brokered sale of newly acquired shares; dollar value and volume are small relative to outstanding stock.

The proposed sale of 6,818 shares for $136,179.70 represents a de minimis fraction of the issuer's 43.47 million shares outstanding, suggesting limited direct market impact. The shares were recently acquired via an equity award and option exercise and are being sold through Merrill Lynch for cash. Prior insider sales in the past three months (16,158 and 868 shares) are disclosed, indicating ongoing liquidity activity by the seller rather than a single large disposition. From a trading-volume perspective, these sizes are unlikely to materially affect valuation.

Corporate Governance Expert

TL;DR Transaction is routine insider disposition; disclosure complies with Rule 144 reporting elements shown.

The filing contains the required elements under Rule 144: broker identity, number of shares, acquisition dates and nature (equity award and option), payment method, and recent sales history by the same person. The signer affirms no undisclosed material adverse information. There is no indication of a trading plan adoption date in the remarks section, and no statements about Rule 10b5-1 reliance are provided. Based solely on the filing, this appears to be a standard disclosure of planned sales rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	6818	136179.70	43470125	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2025	Equity Award	Issuer			2069	09/01/2025	Cash
Common	09/04/2025	Stock Option	Issuer			4749	09/04/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Hopman 11 HUGHES Irvine CA 92618	Common	08/19/2025	16158	268376.10
Mark Hopman 11 HUGHES Irvine CA 92618	Common	06/02/2025	868	15529.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the Beta Bionics (BBNX) Form 144?

The filing reports a proposed brokered sale of 6,818 common shares through Merrill Lynch on 09/04/2025 with aggregate market value of $136,179.70.

How were the shares being sold by the insider acquired?

The shares were acquired as an equity award (2,069 shares on 09/01/2025) and via stock option exercise (4,749 shares on 09/04/2025), with payment listed as cash.

How large is the sale relative to Beta Bionics' outstanding shares?

The proposed sale of 6,818 shares is against 43,470,125 shares outstanding, representing a very small fraction of the total outstanding stock.

Has the seller recently sold other shares of BBNX?

Yes. The filing discloses prior sales by the same person: 16,158 shares on 08/19/2025 and 868 shares on 06/02/2025.

Does the filing state reliance on a Rule 10b5-1 trading plan?

No plan adoption date or explicit reliance on a Rule 10b5-1 trading plan is provided in the remarks section of this filing.